Renal vein thrombosis in a newborn with prothrombotic genetic risk factors

被引:11
作者
Giordano, P
Laforgia, N
Di Giulio, G
Storelli, S
Mautone, A
Iolascon, A
机构
[1] Univ Bari, Dipartimento Biomed Eta Evolut, I-70124 Bari, Italy
[2] Univ Bari, Inst Radiol, I-70124 Bari, Italy
关键词
genetic factors; kidney; newborn; thrombosis;
D O I
10.1515/JPM.2001.023
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Environmental and genetic risk factors interact to cause venous thromboembolism. Renal vein thrombosis in the newborn has been frequently associated with "risk factors" as catheters, surgery or trauma, but it has also been demonstrated a pathogenetic role of generic prothrombotic risk factors, i.e. activated protein C resistance and FV Leiden. The treatment of neonatal venous thrombosis varies worldwide and different approaches have been proposed. We present a case of renal vein thrombosis in a female newborn with normal plasma levels of protein C, protein S and antithrombin LII, but with her genotype characterized by the presence of three prothrombotic risk factors: factor V Leiden, methylentetrahydrofolate reductase and platelet glycoprotein IIIa polymorphisms. The treatment with recombinant tissue plasminogen determined complete thrombus dissolution.
引用
收藏
页码:163 / 166
页数:4
相关论文
共 26 条
[1]   CAVAL THROMBOLYSIS IN NEONATES USING LOW-DOSES OF RECOMBINANT HUMAN TISSUE-TYPE PLASMINOGEN-ACTIVATOR [J].
ANDERSON, BJ ;
KEELEY, SR ;
JOHNSON, ND .
ANAESTHESIA AND INTENSIVE CARE, 1991, 19 (01) :22-27
[2]   DEVELOPMENTAL HEMOSTASIS - RELEVANCE TO HEMOSTATIC PROBLEMS DURING CHILDHOOD [J].
ANDREW, M .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 1995, 21 (04) :341-356
[3]  
BERGER C, 1994, ARCH PEDIATRIE, V1, P1014
[4]   MUTATION IN BLOOD-COAGULATION FACTOR-V ASSOCIATED WITH RESISTANCE TO ACTIVATED PROTEIN-C [J].
BERTINA, RM ;
KOELEMAN, BPC ;
KOSTER, T ;
ROSENDAAL, FR ;
DIRVEN, RJ ;
DERONDE, H ;
VANDERVELDEN, PA ;
REITSMA, PH .
NATURE, 1994, 369 (6475) :64-67
[5]   A common mutation in the methylenetetrahydrofolate reductase gene (C677T) increases the risk for deep-vein thrombosis in patients with mutant factor V (Factor V:Q(506)) [J].
Cattaneo, M ;
Tsai, MY ;
Bucciarelli, P ;
Taioli, E ;
Zighetti, ML ;
Bignell, M ;
Mannucci, PM .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1997, 17 (09) :1662-1666
[6]  
DAHLBACK B, 1995, THROMB HAEMOSTASIS, V74, P1380
[7]   Recombinant tissue-type plasminogen activator therapy of thrombosis in 16 neonates [J].
Farnoux, C ;
Camard, O ;
Pinquier, D ;
Hurtaud-Roux, MF ;
Sebag, G ;
Schlegel, N ;
Beaufils, F .
JOURNAL OF PEDIATRICS, 1998, 133 (01) :137-140
[8]   A CANDIDATE GENETIC RISK FACTOR FOR VASCULAR-DISEASE - A COMMON MUTATION IN METHYLENETETRAHYDROFOLATE REDUCTASE [J].
FROSST, P ;
BLOM, HJ ;
MILOS, R ;
GOYETTE, P ;
SHEPPARD, CA ;
MATTHEWS, RG ;
BOERS, GJH ;
DENHEIJER, M ;
KLUIJTMANS, LAJ ;
VANDENHEUVEL, LP ;
ROZEN, R .
NATURE GENETICS, 1995, 10 (01) :111-113
[9]   Intermediate and severe hyperhomocysteinemia with thrombosis: A study of genetic determinants [J].
Gaustadnes, M ;
Rudiger, N ;
Rasmussen, K ;
Ingerslev, J .
THROMBOSIS AND HAEMOSTASIS, 2000, 83 (04) :554-558
[10]  
Giordano P, 1998, THROMB RES, V91, pS36